weight loss glp-1 agonists Comparing Ozempic, Wegovy and Other Drugs Unlocking The Power of GLP-1

In the STEP 1 trial extension, 327 participants were assessed for one year after discontinuing semaglutide 2.4 mg and lifestyle intervention

Body weight and food intake were subsequently monitored daily in the afternoon

Gastroenterol Clin N Am

A recent randomized placebo-controlled trial published by Scirica et al, known as SAVOR-TIMI 53, found no significant difference in ischemic events but did observe higher hospitalizations for heart failure with saxagliptin

Commonly experienced symptoms include nausea, vomiting, and abdominal pain

This increased risk was confined to women using GLP-1 receptor agonists for diabetes treatment (liraglutide aOR 1.70, 95% CI 1.172.48